A Phase 4 interventional study of Vedolizumab and Placebo in Crohn's Disease, sponsored by Takeda. Completed at 18 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 33rd largest by enrollment, is one of 7 that started in 2016, is one of 14 in phase 4, and was the 12th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 40th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2016, is one of 10 in phase 4, and was the 19th registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).
The drug being tested in this study is called vedolizumab IV. Vedolizumab IV is being tested to treat people who have fistulizing CD. This study will look at fistula healing in people who take vedolizumab IV.
The study is planned to enroll approximately 100 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
This multi-center trial will be conducted worldwide. The overall time to participate in this study from screening to 18 weeks after the last dose is 44 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 6 months after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All countries except France: The participant, historically, had an inadequate response with, lost response to, or was intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-α) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula).
France only: The participant, historically, failed (ie, had an inadequate response with, lost response to, or was intolerant to) infliximab for treatment of their underlying CD or fistulizing CD.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
Drug: Vedolizumab · Drug: Placebo
Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
Drug: Vedolizumab
Vedolizumab 300 mg IV infusion
Also known as: Entyvio, MLN0002, Kynteles
0.9% sodium chloride IV infusion
Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline)
Closed fistulae are no longer draining despite gentle finger compression.
Time frame: Baseline, Week 30
Percentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 30
Closed fistulae are no longer draining despite gentle finger compression.
Time frame: Weeks 22 and 30
Percentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline)
Closed fistulae are no longer draining despite gentle finger compression.
Time frame: Week 30
Time to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)
Closed fistulae are no longer draining despite gentle finger compression.The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.
Time frame: Up to Week 30
Time to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)
Closed fistulae are no longer draining despite gentle finger compression. The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.
Time frame: Up to Week 30
Duration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline)
Duration of fistula response was measured by number of days with/without drainage. Duration of perianal fistula response (days) was derived as the sum of days with perianal fistula response between Day 1 and the end of the study (Week 30 or early discontinuation). Perianal fistula response is defined as reduction in the number of draining perianal fistulae (of those draining at Baseline) draining of at least 50%.
Time frame: Up to Week 30
Participants took part in the study at 13 investigative sites in Canada, France, Italy, the Netherlands, Spain, the United Kingdom, and the United States from 10 August 2016 to 14 November 2018.
| Milestone | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Started | 16 | 18 |
| Completed | 14 | 10 |
| Not completed | 2 | 8 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Significant protocol deviation | 0 | 2 |
| Withdrew: Voluntary withdrawal | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 |
Closed fistulae are no longer draining despite gentle finger compression.
| percentage of participants | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) | 75.0 (50.5 to 99.5) | 75.0 (45.0 to 100.0) |
Closed fistulae are no longer draining despite gentle finger compression.
| percentage of participants | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 30 | 72.7 (46.4 to 99.0) | 62.5 (24.5 to 91.5) |
Closed fistulae are no longer draining despite gentle finger compression.
| percentage of participants | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Percentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline) | 58.3 (30.4 to 86.2) | 62.5 (24.5 to 91.5) |
Closed fistulae are no longer draining despite gentle finger compression.The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.
| days | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Time to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline) | 30.5 (15.0 to 71.0) | 159.0 (16.0 to NA) |
Closed fistulae are no longer draining despite gentle finger compression. The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.
| days | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Time to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline) | 45.0 (15.0 to 155.0) | 159.0 (16.0 to NA) |
Duration of fistula response was measured by number of days with/without drainage. Duration of perianal fistula response (days) was derived as the sum of days with perianal fistula response between Day 1 and the end of the study (Week 30 or early discontinuation). Perianal fistula response is defined as reduction in the number of draining perianal fistulae (of those draining at Baseline) draining of at least 50%.
| days | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Duration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline) | 158.5 (0 to 202) | 33.5 (0 to 203) |
Collected over Up to approximately 44 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Vedolizumab IV 300 mg + Placebo | 0/16 (0%) | 4/16 (25%) | 15/16 (93.8%) |
| Group 2: Vedolizumab 300 mg | 0/18 (0%) | 3/18 (16.7%) | 17/18 (94.4%) |
| Event | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Anal abscessInfections and infestations | 3/16 | 0/18 |
| Crohn's diseaseGastrointestinal disorders | 1/16 | 1/18 |
| Ileal stenosisGastrointestinal disorders | 1/16 | 0/18 |
| Abdominal infectionInfections and infestations | 1/16 | 0/18 |
| HyperpyrexiaGeneral disorders | 0/16 | 1/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/16 | 1/18 |
| Event | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/16 | 5/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/16 | 5/18 |
| Abdominal painGastrointestinal disorders | 4/16 | 2/18 |
| PyrexiaGeneral disorders | 2/16 | 4/18 |
| HeadacheNervous system disorders | 2/16 | 4/18 |
| Anal abscessInfections and infestations | 3/16 | 0/18 |
| ProctalgiaGastrointestinal disorders | 2/16 | 0/18 |
| Anal fistulaGastrointestinal disorders | 2/16 | 2/18 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/16 | 0/18 |
| VomitingGastrointestinal disorders | 0/16 | 2/18 |
The Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 35.1 ± 10.35 | 35.1 ± 10.67 | 35.1 ± 10.36 |
| Sex: Female, Male(Participants) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 10 | 11 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 3 | 5 |
| Unknown or Not Reported | 14 | 15 | 29 |
| Race (NIH/OMB)(Participants) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 12 | 15 | 27 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Region of Enrollment(Participants) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Canada | 1 | 0 | 1 |
| France | 2 | 3 | 5 |
| Italy | 5 | 6 | 11 |
| Netherlands | 2 | 3 | 5 |
| Spain | 3 | 2 | 5 |
| United Kingdom | 1 | 1 | 2 |
| United States | 2 | 3 | 5 |
| Height(centimeter (cm)) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 170.1 ± 6.35 | 176.4 ± 10.38 | 173.4 ± 9.17 |
| Weight(kilograms (kg)) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 73.65 ± 15.986 | 68.36 ± 14.661 | 70.85 ± 15.299 |
| Body Mass Index (BMI)(kg per square meter (kg/m^2)) | Group 1: Vedolizumab IV 300 mg + Placebo | Group 2: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 25.40 ± 5.080 | 21.84 ± 3.580 | 23.52 ± 4.646 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Aug 2016 to primary completion in Sep 2018, 24 months.
Results were first posted in Sep 2019, 1 year after primary completion.
Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab